Ann: 2021 EGM Presentation, page-13

It appears the PD-(L)1 honeymoon is finally over.
Incyte revealed late Friday the FDA has slammed its PD-1 retifanlimab — which was under priority review for locally advanced or metastatic squamous cell carcinoma of the anal canal — with a complete response letter, demanding “additional data” to show clinical benefit.
it also signals an official shift in the agency’s handling of checkpoint blockers, if not cancer drugs in general: Five years after the landmark first approval for Merck’s Keytruda, and with eight PD-(L)1 drugs on the market, there will be no more easy passes.

And the honeymoon period for LAG-3 and 'efti' is just beginning....in multiple combination settings, including approved PD-1 drug makers who will likely need a USP (unique selling proposition) to maintain or increase their market share.....